# Norovirus Challenge Study

> **NCT05212168** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vaxart** · enrollment: 165 (actual)

## Conditions studied

- Norovirus Infections

## Interventions

- **BIOLOGICAL:** VXA-G1.1-NN
- **OTHER:** Placebo Tablets
- **BIOLOGICAL:** Norovirus GI.1 Norwalk Virus Inoculum

## Key facts

- **NCT ID:** NCT05212168
- **Lead sponsor:** Vaxart
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-27
- **Primary completion:** 2023-04-13
- **Final completion:** 2023-10-27
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2025-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05212168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05212168, "Norovirus Challenge Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05212168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*